Biotech firm’s nanotechnology aims to enhance cancer treatment efficacy, reduce side effects

Dec. 19, 2024, Ann Arbor, Michigan – Peptinovo Biopharma, an Ann Arbor-based biopharma company, has successfully closed $1.4 million in funding as part of its Series A round. The milestone kicks off a campaign to raise $10 million to enable Peptinovo to move its drug-delivery platform to clinical trials.

Incorporated in 2020 by experienced biotech pharmaceutical entrepreneurs, Peptinovo is pioneering PALMTM, to deliver proven chemotherapeutic drugs directly into cancer tumors, with the aim of increasing the efficacy of the drugs and reducing serious, and often long-term, side effects for patients and survivors.

The company’s patented smart drug-delivery platform exploits a mechanism cancer cells use to grow. Like a Trojan Horse, PALMTM transports the chemotherapy drugs directly to cancer cells. PALMTM is designed to enhance the effectiveness of proven chemotherapies across a wide range of solid cancerous tumors, while significantly reducing the serious side effects that limit the success of traditional treatments.

“PALM’s platform could allow existing chemotherapies to reach their full potential, while allowing patients to live normal lives,” Peptinovo CEO Steve Tokarz said. “The Series A raise is off to a strong start. Now, we’re working to finance the remaining $8.6 million to advance our technology into the hands of doctors and patients. The patient is waiting.”

In its fundraising strategy, Peptinovo is using a hybrid approach, combining Regulation D accredited-investor funding with Regulation CF crowdfunding. This model reflects the future of fundraising, enabling broader participation in private investment opportunities.

Interested investors should contact Peptinovo CEO Steve Tokarz.

About Peptinovo Biopharma Peptinovo Biopharma is a pre-clinical biotechnology company specializing in the PALMTM patented smart drug-delivery platform aimed at improving the efficacy of approved chemotherapies for solid tumors while minimizing their side effects. For more information, visit https://peptinovo.com/.